$51.43 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter

Equities analysts expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post sales of $51.43 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Vanda Pharmaceuticals’ earnings, with estimates ranging from $49.70 million to $53.00 million. Vanda Pharmaceuticals reported sales of $44.28 million in the same quarter last year, which would suggest a positive year over year growth rate of 16.1%. The company is scheduled to report its next earnings report on Wednesday, February 13th.

According to Zacks, analysts expect that Vanda Pharmaceuticals will report full year sales of $190.35 million for the current year, with estimates ranging from $189.00 million to $191.70 million. For the next year, analysts expect that the business will post sales of $243.07 million, with estimates ranging from $229.00 million to $261.30 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Vanda Pharmaceuticals.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.13 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.18. Vanda Pharmaceuticals had a net margin of 0.73% and a return on equity of 0.68%. The company had revenue of $49.13 million for the quarter, compared to the consensus estimate of $49.44 million. During the same period in the prior year, the firm posted ($0.03) EPS. The company’s quarterly revenue was up 18.9% compared to the same quarter last year.

A number of equities research analysts have commented on VNDA shares. Cantor Fitzgerald reissued a “hold” rating and issued a $26.00 price objective on shares of Vanda Pharmaceuticals in a research report on Wednesday, October 3rd. Oppenheimer set a $29.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday. Stifel Nicolaus set a $31.00 price objective on shares of Vanda Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday. Citigroup increased their target price on shares of Vanda Pharmaceuticals from $27.00 to $31.00 and gave the company a “buy” rating in a research report on Tuesday, October 16th. Finally, Zacks Investment Research raised shares of Vanda Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Friday, October 12th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Vanda Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $27.43.

Shares of NASDAQ:VNDA opened at $23.81 on Friday. Vanda Pharmaceuticals has a 52 week low of $11.90 and a 52 week high of $25.07. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -68.03 and a beta of 1.06.

Several hedge funds and other institutional investors have recently bought and sold shares of VNDA. Metropolitan Life Insurance Co. NY increased its stake in Vanda Pharmaceuticals by 18.4% during the second quarter. Metropolitan Life Insurance Co. NY now owns 17,187 shares of the biopharmaceutical company’s stock valued at $327,000 after purchasing an additional 2,671 shares during the last quarter. Allianz Asset Management GmbH grew its position in shares of Vanda Pharmaceuticals by 2.9% during the first quarter. Allianz Asset Management GmbH now owns 136,218 shares of the biopharmaceutical company’s stock worth $2,295,000 after acquiring an additional 3,903 shares during the last quarter. MetLife Investment Advisors LLC grew its position in shares of Vanda Pharmaceuticals by 20.0% during the second quarter. MetLife Investment Advisors LLC now owns 24,336 shares of the biopharmaceutical company’s stock worth $464,000 after acquiring an additional 4,063 shares during the last quarter. Strs Ohio grew its position in shares of Vanda Pharmaceuticals by 9.7% during the second quarter. Strs Ohio now owns 47,500 shares of the biopharmaceutical company’s stock worth $904,000 after acquiring an additional 4,200 shares during the last quarter. Finally, Fox Run Management L.L.C. grew its position in shares of Vanda Pharmaceuticals by 23.9% during the second quarter. Fox Run Management L.L.C. now owns 28,611 shares of the biopharmaceutical company’s stock worth $545,000 after acquiring an additional 5,516 shares during the last quarter. 93.92% of the stock is currently owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Featured Article: What is intrinsic value?

Get a free copy of the Zacks research report on Vanda Pharmaceuticals (VNDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply